Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management

G Garcia‐Manero - American journal of hematology, 2023 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

RF Duarte, M Labopin, P Bader, GW Basak… - Bone marrow …, 2019 - nature.com
This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

JA Snowden, I Sánchez-Ortega… - Bone marrow …, 2022 - nature.com
For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Eltrombopag added to immunosuppression in severe aplastic anemia

R Peffault de Latour, A Kulasekararaj… - … England Journal of …, 2022 - Mass Medical Soc
Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …

[HTML][HTML] Thrombopoietin receptor agonists: ten years later

W Ghanima, N Cooper, F Rodeghiero, B Godeau… - …, 2019 - ncbi.nlm.nih.gov
The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …

Eltrombopag added to standard immunosuppression for aplastic anemia

DM Townsley, P Scheinberg, T Winkler… - … England Journal of …, 2017 - Mass Medical Soc
Background Acquired aplastic anemia results from immune-mediated destruction of bone
marrow. Immunosuppressive therapies are effective, but reduced numbers of residual stem …

Guidelines for the use of platelet transfusions

L Estcourt, J Birchall, S Allard, S Bassey… - British journal of …, 2016 - ora.ox.ac.uk
The demand for platelets in England was stable at around 220,000 adult therapeutic doses
(ATD) per year until 2007/8 at which point demand has increased year on year to 275,000 …

Modulating the stem cell niche for tissue regeneration

SW Lane, DA Williams, FM Watt - Nature biotechnology, 2014 - nature.com
The field of regenerative medicine holds considerable promise for treating diseases that are
currently intractable. Although many researchers are adopting the strategy of cell …

[HTML][HTML] Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies

DJ Kuter - Haematologica, 2022 - ncbi.nlm.nih.gov
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment
of non-hematologic malignancies. Many patient-related variables (eg, age, tumor type …

[图书][B] Hematology E-Book: Basic Principles and Practice

R Hoffman, EJ Benz, LE Silberstein, H Heslop, J Weitz… - 2022 - books.google.com
Extensively revised, comprehensive content from leading global contributors ensures that
Hematology, 8th Edition, remains your# 1 choice for expert guidance in all areas of this …